Table 2.
Clinical characteristics and CR rates for patients with CBF AML with and without KIT mutations
| KIT mutation+ | WT KIT | P | |
|---|---|---|---|
| Total, n | 38 | 165 | |
| Sex | |||
| Male, n (%) | 22 (58) | 84 (51) | .437 |
| Female, n (%) | 16 (42) | 81 (49) | |
| Age, y | |||
| Median (range) | 10.5 (1.1-16.6) | 12.0 (0.6-19.6) | .127 |
| 0 to younger than 2 y, n (%) | 4 (11) | 6 (4) | .077 |
| 2 to younger than 10 y, n (%) | 14 (37) | 55 (33) | .681 |
| 10-21 y, n (%) | 20 (53) | 104 (63) | .236 |
| Race | |||
| White, n (%) | 23 (61) | 108 (66) | .504 |
| Nonwhite, n (%) | 15 (39) | 55 (34) | |
| Unknown, n | 0 | 2 | |
| WBC count, median (range) | 33.5 (3.9-379) | 27.1 (1.6-373) | .477 |
| BM blasts, %, median (range) | 56 (0-92) | 52 (0-99) | .915 |
| Additional mutations | |||
| FLT3/ITD | |||
| Negative, n (%) | 31 (100) | 139 (96) | .592 |
| Positive, n (%) | 0 (0) | 6 (4) | |
| NPM1 | |||
| Negative, n (%) | 17 (100) | 110 (100) | > .999 |
| Positive, n (%) | 0 (0) | 0 (0) | |
| CEBPA | |||
| Negative, n (%) | 21 (100) | 103 (100) | > .999 |
| Positive, n (%) | 0 (0) | 0 (0%) | |
| WT-1 | |||
| Negative, n (%) | 22 (100) | 96 (88) | .124 |
| Positive, n (%) | 0 (0) | 13 (12) | |
| BM blasts, %, median (range) | 56 (0-92) | 52 (0-99) | .195 |
| Induction response | |||
| CR, n (%) | 36 (97) | 144 (94) | .690 |
| Not in CR, n (%) | 1 (3) | 9 (6) | |
| Unevaluable or withdrew, n | 1 | 12 |
CBF AML indicates core binding factor acute myeloid leukemia; WT, wild-type; WBC, white blood cell; BM, bone marrow; FLT3/ITD, FLT3 internal tandem duplication; NPM1, nucleophosmin; CEBPA, CCAAT/enhancer binding protein-α; WT-1, Wilms tumor gene 1; and CR, complete remission.